ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0272

Combined Effects of GLP-1 Receptor Agonist and SGLT2 Inhibitor on Inflammatory Modulation in Hypoxia-Induced Renal Tubular and Endothelial Cell Injury

Session Information

Category: Hypertension and CVD

  • 1601 Hypertension and CVD: Basic

Authors

  • Oliveira, Julia Cristine, Universidade Federal de Sao Paulo, São Paulo, SP, Brazil
  • de Jesus, Thais Silva, Universidade Federal de Sao Paulo, São Paulo, SP, Brazil
  • Figueredo, Guilherme Rocha, Universidade Federal de Sao Paulo, São Paulo, SP, Brazil
  • Brasil, Giulia Quinto, Universidade Federal de Sao Paulo, São Paulo, SP, Brazil
  • Quinto, Beata M r, Universidade Federal de Sao Paulo, São Paulo, SP, Brazil
  • Batista, Marcelo Costa, Universidade Federal de Sao Paulo, São Paulo, SP, Brazil

Group or Team Name

  • LORDc - UNIFESP.
Background

Chronic low-grade inflammation in obesity plays a key role in kidney and cardiovascular disease. MicroRNAs regulate adipose–endothelial signaling, modulating inflammation, metabolism and insulin sensitivity. GLP-1 receptor agonists and SGLT2 inhibitors have shown reno- and cardioprotective effects, but their combined impact on hypoxia-induced inflammation and injury is poorly defined.

Methods

HK-2 and HUVECs were exposed to six conditions: control, hypoxia, hypoxia + inflammation (leptin + TGF-β), and inflammation plus liraglutide (GLP-1 RA), dapagliflozin (SGLT2i), or both. Cytokines (leptin, IL-6, TNF-α, IL-10, IL-1β), NGAL and KIM-1 were measured by multiplex immunoassay and HIF1α, ICAM, VCAM, TNF-α, and IL-10 expression, by immunofluorescence. ANOVA with Bonferroni correction was used (p < 0.05).

Results

The inflammatory model significantly elevated leptin, TNF-α, and IL-6 levels in both HK-2 and HUVECs (p < 0.05). HUVECs also demonstrated increased IL-10, NGAL and KIM-1. Co-treatment with liraglutide and dapagliflozin reduced proinflammatory cytokines and tubular injury markers in both cells, though not all changes achieved statistical significance. Immunofluorescence confirmed upregulation of HIF1α, ICAM, VCAM, TNF-α, and IL-10 in HK-2 cells under inflammatory conditions, which was attenuated by the combination therapy.

Conclusion

Hypoxia combined with leptin and TGF-β induces a robust proinflammatory and injurious response in renal tubular and endothelial cells. Combined treatment with liraglutide and dapagliflozin effectively mitigates these effects, supporting a synergistic anti-inflammatory and renoprotective role. These findings provide mechanistic insight into the potential of dual GLP-1 RA and SGLT2i therapy for mitigating kidney injury in metabolic disease contexts.

Funding

  • Government Support – Non-U.S.

Digital Object Identifier (DOI)